News articles about GenMark Diagnostics (NASDAQ:GNMK) have been trending positive on Friday, AlphaOne Sentiment Analysis reports. The research group, a division of Accern, scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a news impact score of 0.39 on AlphaOne’s scale. AlphaOne also assigned media headlines about the medical equipment provider an impact score of 83 out of 100, indicating that recent press coverage is very likely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Alpha One’s analysis:
- GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel (businesswire.com)
- GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- CORRECTING and REPLACING GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel (finance.yahoo.com)
- In-Vitro Diagnostics Market 2017: Top 100 U.S. Manufacturers, Historic Growth, Trends, Strategies and Key Competitor Shares to 2021 (medgadget.com)
- GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 (finance.yahoo.com)
Several research analysts recently weighed in on GNMK shares. BTIG Research restated a “buy” rating and set a $17.00 price target on shares of GenMark Diagnostics in a report on Friday, March 10th. Zacks Investment Research upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, March 3rd. Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of GenMark Diagnostics in a report on Wednesday, April 5th. Finally, Canaccord Genuity set a $14.00 price target on shares of GenMark Diagnostics and gave the stock a “buy” rating in a report on Monday, January 23rd. Six investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $15.00.
GenMark Diagnostics (NASDAQ:GNMK) traded down 3.55% on Friday, reaching $12.50. 313,091 shares of the company’s stock were exchanged. The company’s market cap is $588.14 million. The firm’s 50 day moving average price is $12.68 and its 200 day moving average price is $12.04. GenMark Diagnostics has a 52-week low of $5.13 and a 52-week high of $13.62.
GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings results on Tuesday, February 28th. The medical equipment provider reported ($0.27) earnings per share for the quarter, meeting the consensus estimate of ($0.27). GenMark Diagnostics had a negative net margin of 98.17% and a negative return on equity of 114.35%. The business had revenue of $14.90 million for the quarter, compared to the consensus estimate of $15.03 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, analysts expect that GenMark Diagnostics will post ($0.96) earnings per share for the current year.
In other GenMark Diagnostics news, CFO Scott Mendel sold 8,595 shares of GenMark Diagnostics stock in a transaction that occurred on Tuesday, February 21st. The shares were sold at an average price of $10.08, for a total transaction of $86,637.60. Following the transaction, the chief financial officer now owns 102,761 shares of the company’s stock, valued at $1,035,830.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jon Faiz Kayyem sold 5,250 shares of GenMark Diagnostics stock in a transaction that occurred on Tuesday, February 21st. The shares were sold at an average price of $10.08, for a total transaction of $52,920.00. Following the transaction, the senior vice president now directly owns 154,079 shares in the company, valued at approximately $1,553,116.32. The disclosure for this sale can be found here. Insiders have sold 49,444 shares of company stock worth $501,739 in the last ninety days. Insiders own 7.09% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “GenMark Diagnostics (GNMK) Given Media Impact Score of 0.39” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2486190/genmark-diagnostics-gnmk-given-media-impact-score-of-0-39.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.
Receive News & Ratings for GenMark Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.